Realistic Problems and Development Suggestions of China's Medication Assurance System for Rare Diseases


  • Xinying Yang
  • Yongfa Chen



Rare diseases, medication for rare diseases, medication assurance.


This study analyses the current situation and existing problems of China's rare disease medication Assurance practice in terms of policy system, main body's actions and protection effectiveness: from the perspective of policy design and the three main bodies' practical actions, the current situation of China's rare disease medication assurance is sorted out; based on this, the real problems of the current protection system in terms of the formulation of front-end policies and the actual benefits for end patients are clarified. Based on this, we will optimise the level of drug protection for rare diseases in China, and put forward specific recommendations: systematic construction of the top-level design for rare diseases, value assessment and payment agreement for innovative drugs in medical insurance, innovation and development of the medical emphasis system and talent cultivation, and improvement of the incentive system for market exclusivity and research and development of drugs for rare diseases.


Download data is not yet available.


J.H. Chang, Y.H. Zhao, X.Y. Zheng, et al.: Status quo of newborn screening and patient registration for rare diseases, Chinese Journal of Public Health, vol. 37 (2021) No. 6, p.1027-1030.

Y.C. Gu, D.He, H.Sun, et al.: A Study on the Problems and Paths of Landing Negotiated Rare Disease Drugs in the National Health Insurance Drug Catalogue Based on Smith's Policy Implementation Process Model, Chinese Health Resources, vol. 26 (2023) No. 4, p.363-369.

L.K. Li, X.Y. Tao: Present situation and prospect of diagnosis, treatment and guarantee of rarediseases in China, Chinese Journal of New Drugs and Clinical Remedies, vol. 42 (2023) No. 2, p.65-70+60

M. Jin, A.X. Ma: Research on the Policies of Rare Diseases and Orphan Drug Supply SecurityModes in Jiangsu Province, China Journal of Pharmaceutical Economics, vol. 13 (2010) No. 3, p.93-101.

Y.H. Zhao, R. Huang, Q.T. Wang, et al.: Incentive Policy System and Its Impact Analysis on Promoting the Accessibility of Orphan Drugs in China, Herald of Medicine, vol. 41 (2022) No. 12, p.1771-1776.

L.L. Li, X.T. He, X.Y. Chen, et al.: Research on Current Situation and Optimized Path of Drug Use Systems of RareDiseases in China, China Health Insurance, (2022) No. 9, p.116-119.

K. Zhu: Medical security mechanism for rare diseases:experience and implication fromsome countries and regions, Journal of Nanjing Medical University(Social Sciences), vol. 22 (2022) No. 1, p.1-5.

Y.R. Li, H. Ding, X. Su: Analysis and prospect of status of orphan drug research, Journal of International Pharmaceutical Research, vol. 44 (2017) No. 2, p.107-111.

B. Wu, R.X. Luo, J.P. Cao, et al.: The Current Status and Strategies of Medical Security of Patients with Rare Diseases in Fujian, Chinese Health Economics, vol. 36 (2017) No. 3, p.37-39.

Y.H. Li, G.Z. Tang: Affordability Evaluation of Drugs for Rare Diseases and Research on MedicalInsurance Policy, Health Economics Research, vol. 39 (2022) No. 4, p.53-57.

Y.C. Gu, Q.H. Zhang, Z. Huang, et al.: Guarantee Mechanism for the Use of High-Value Rare Drugs in Korea, Chinese Health Resources, vol. 24 (2021) No. 6, p. 641-645+825.







How to Cite

Yang, X., & Chen, Y. (2024). Realistic Problems and Development Suggestions of China’s Medication Assurance System for Rare Diseases. Frontiers in Humanities and Social Sciences, 4(6), 37-45.